+

WO2011004379A1 - Compositions et méthodes de traitement du cancer - Google Patents

Compositions et méthodes de traitement du cancer Download PDF

Info

Publication number
WO2011004379A1
WO2011004379A1 PCT/IL2010/000554 IL2010000554W WO2011004379A1 WO 2011004379 A1 WO2011004379 A1 WO 2011004379A1 IL 2010000554 W IL2010000554 W IL 2010000554W WO 2011004379 A1 WO2011004379 A1 WO 2011004379A1
Authority
WO
WIPO (PCT)
Prior art keywords
fzd7
cells
cancer
ncam
targeting moiety
Prior art date
Application number
PCT/IL2010/000554
Other languages
English (en)
Inventor
Benjamin Dekel
Naomi Pode-Shakked
Gilmor Iris Keshet
Original Assignee
Tel Hashomer Medical Research Infrastructure And Services Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tel Hashomer Medical Research Infrastructure And Services Ltd. filed Critical Tel Hashomer Medical Research Infrastructure And Services Ltd.
Publication of WO2011004379A1 publication Critical patent/WO2011004379A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Definitions

  • the present invention in some embodiments thereof, relates to compositions and methods for treating cancer, specifically, pediatric cancers having embryonic stems cell origin, such as WiIm 's tumor.
  • WT Wilms tumor
  • WT is believed to result from malignant transformation of abnormally persistent renal stem cells which retain embryonic differentiation potential.
  • recent molecular data obtained by microarrays demonstrate that WTs and WT-stem like xenografts systematically overexpress nephric-progenitor genes corresponding to the earliest stages of normal metanephric kidney development [Dekel et al., 2006a; Li et al., 2002; Metsuyanim et al., 2008)], connecting tumorigenesis and organogenesis in the kidney [Rivera & Haber, 2005].
  • Wnt pathway-related molecules including b-catenin (CTNNBl), frizzled7 (FZD7) and frizzled2 (FZD2)
  • CNNBl b-catenin
  • FZD7 frizzled7
  • FZD2 frizzled2
  • cancer stem cells are often biologically distinct from the differentiated cancer cells that comprise most of the tumor bulk. Because cancer stem cells are believed to be primarily responsible for tumor initiation as well as resistance to chemo- and radiotherapy, their persistence may account for relapsing disease in WT [Bao et al, 2006; Clarke et al, 2006; Galmozzi et al, 2006; Reya et al, 2001].
  • NCAM + cell population was defined that is a strong candidate for the tumor stem/progenitor cell population (Pode Shakked et al., 2008).
  • FZD7 the over-expressed Wnt receptor
  • U.S. Application Number 20090111177 relates to methods for maintaining the undifferentiated state of embryonic stem cells without the use of a feeder layer by activating the Wnt signal transduction pathway or by inhibiting glycogen synthase kinase-3 activity by contacting the cell with, inter alia, 6-bromoindirubin-3'-oxime.
  • U.S. Application Number 20060019256 provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, and treatment of solid tumor stem cells.
  • an article of manufacture comprising a cytotoxic moiety and an NCAM targeting moiety.
  • composition of matter comprising a cytotoxic moiety attached to an NCAM targeting moiety.
  • a pharmaceutical composition comprising as active ingredients a cytotoxic moiety and an NCAM targeting moiety and a pharmaceutically acceptable carrier or diluent.
  • an article of manufacture comprising a FZD7 targeting moiety and an agent capable of inhibiting the Wnt pathway.
  • a pharmaceutical composition comprising as active ingredients FZD7 targeting moiety and an agent capable of inhibiting the Wnt pathway and a pharmaceutically acceptable carrier or diluent.
  • a method of killing a cancer cell expressing NCAM and optionally FZD7 comprising contacting the cancer cell with a cytotoxic moiety and an NCAM targeting moiety, thereby killing the cancer cell.
  • a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a cytotoxic moiety and an NCAM targeting moiety, thereby treating the cancer.
  • cytotoxic moiety and an NCAM targeting moiety for the treatment of cancer.
  • a method of killing a cancer cell expressing FZD7 and optionally NCAM comprising contacting the cancer cell with an FZD7 targeting moiety and an agent capable of inhibiting the Wnt pathway, thereby killing the cancer cell.
  • a method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an FZD7 targeting moiety and an agent capable of inhibiting the Wnt pathway, thereby treating the cancer.
  • the method further comprises determining an expression level of FZD7 and additionally or alternatively NCAM in the cancer cell prior to the contacting. According to some embodiments of the invention, the method further comprises determining an expression level of FZD7 and additionally or alternatively NCAM in cells of the cancer prior to the administering.
  • the cytotoxic moiety comprises an agent capable of inhibiting the Wnt pathway.
  • the agent comprises an FZD7 targeting moiety.
  • the FZD7 targeting moiety comprises an anti FZD7 antibody.
  • the cytotoxic moiety comprises a chemotherapy, a toxin, a cytokine, an antibody or a radiotherapy.
  • the agent comprises DKKl and sFRPl.
  • ihe agent comprises a demethylating agent.
  • the cancer is a pediatric cancer having an embryonic stem cell origin.
  • the pediatric cancer having an embryonic stem cell origin comprises WiIm 's tumor.
  • the cytotoxic moiety and the NCAM targeting moiety are covalently attached.
  • the cytotoxic moiety and the NCAM targeting moiety are non-covalently attached.
  • the cytotoxic moiety and the NCAM targeting moiety are not attached.
  • the composition comprises a bispecific antibody.
  • all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
  • FIGs. IA-S illustrate enhanced WT Cell death after exposure to anti FZD7 antibody in the FZD7-sensitive but not in the resistant WTs.
  • FIG. IJ-R FZD7-resistant WTs
  • Figure IS Summary of FACS analysis results for 7-AAD staining (dead cells) in the sensitive and resistant tumors at 6 different anti-FZD7 concentrations showing an increase in the percentages of dead cells following elevation in Ab concentrations only in the FZD7-sensitive WT (red line), while no significant increase in dead cells was observed in the FZD7-resistant WT (blue line).
  • FIGs. 2A-H are FACS plots of one experiment at 4 representative concentrations (from left to right in ⁇ g/ml - 0, 18.3, 75, 150) of anti-FZD7 Ab showing a significant increase in the percentage of 7-AAD + cells only in the FZD7-sensitive WT (upper panel);
  • FIGs. 21- J are FACs plots illustrating the percentages of cells expressing FZD7 receptor on their surface (10.5%) correlates to the percentages of 7-AAD + cells (8.4%) only in the FZD7-sensitive WT (Sensitive - upper panel) while no correlation is seen for the FZD7-resistant WT (Resistant - lower panel).
  • FIGs. 3A-L are photographs illustrating Anti FZD7 Antibody-induced endocytosis.
  • WOO4 and WOlO cells were grown on glass coverslips, incubated with monoclonal anti-FZD7 antibody for 60 minutes at 4 0 C, washed and subsequently shifted to 37 0 C for the indicated time periods. The reaction was stopped by placing the cells on ice. Cells were labeled with Alexafluor 488-conjugated secondary Ab. DAPI nucleic acid stain (blue), was used.
  • Figures 3A-C represents FZD7-resistant WT while Figures 3D-F shows FZD7-sensitive WT.
  • White arrows indicate accumulation of the Ab-FZD7 complex in a single perinuclear organelle for the FZD7-resistant WT and in multiple, dispersed organelles for the FZD7-sensitive WT;
  • Figures 3 G-J Nuclear fragmentation was detected after 30min (left panels) and 60min (right panels) incubation periods with the Ab in the FZD7-sensitive WT.
  • White arrows indicate nuclear fragmentation;
  • Figures 3K-L Right image is the Z section of the left image. Scale Bars dimensions are indicated in the images.
  • FIGs. 4A-N are graphs and photographs illustrating in vitro depletion of potential WT stem cell population following treatment with anti- FZD7 Ab.
  • A-D Evaluation of sphere formation after treatment with anti FZD7 Ab for 3 time periods in FZD7-sensitive WT (A). Number of spheres formed after each incubation period is shown. After 4h incubation with the Ab, no sphere formation was detected.
  • B-D Evaluation of sphere formation after treatment with anti FZD7 Ab for 3 time periods in FZD7-sensitive WT
  • FIGs. 5A-G are photographs illustrating reduced survival/proliferation of anti- FZD7 Ab treated WT cells grafted to the chick embryo chorioallantoic membrane (CAM).
  • A Tumor nodules formed by dissociated WT cells seven days after grafting to the chick. The nodules are fluorescently labeled with the vital dye CFSE. The arrow indicates a large blood vessel in the CAM. Illustration of WT cell transplantation to the CAM of the fertile chick egg;
  • B&C FZD7 Ab treatment reduces size of tumors formed on the CAM.
  • B large masses of human proliferating cells, usually identifiable by their larger nuclei, are present, their boundaries are indicated by dotted lines.
  • NCAM is only observed on human WT cells in grafts not treated with FZD7 Ab. NCAM is a surface marker found on potential WT stem/progenitor cells. Confocal micrographs show that many cells in untreated control tumors (arrow in F) on the CAM are positive for NCAM (D&F green surface staining), while none of the WT cells treated with anti-FZD7 antibody are NCAM + . This staining pattern was observed in all examined sections of both untreated and treated grafts. Figures 5F and G show only the NCAM and nuclear staining for clarity and nuclei in B-G are stained with Hoechst (blue).
  • FIGs. 6A-N are graphs and photographs illustrating FZD7-resistant WTs show nuclear ⁇ -catenin staining and very low expression levels of Wnt pathway inhibitors relative to the FZD7-sensitive WTs
  • FIG. 6A-I Immunofluorescence staining to evaluate the expression of ⁇ - catenin in different cell types.
  • a human epithelium cell line (A) was used as positive control, while a human fibroblast cell line (B) with or (C) without primary antibody was used as negative control, ⁇ - catenin immunostaining was performed on FZD7-resistant WTs (D) WOO2, (E) WOO4, (F) WOO7 - lower panels demonstrate nuclear staining of ⁇ - catenin in these tumors, as well as on FZD7-sensitive WTs (J) WOO5, (K) WOO6, and (L) WOlO showing very little to no staining.
  • FIGs. 7A-R are plots illustrating addition of the Wnt pathway inhibitors, sFRPl, DKKl to WT cells treated with anti FZD7 antibody sensitizes the FZD7-resistant WT to anti-FZD7 antibody.
  • FIGs. 8A-H are graphs and plots illustrating that demethylating agents
  • AzaC+TSA restore the Wnt inhibitors expression to the highest levels in the FZD7- resistant WTs in comparison to the FZD7-sensitive WTs.
  • Transcript levels were normalized to the expression of GAPDH;
  • D FZD7-resistant WT (WOO4, WOO7) either untreated or treated with anti FZD7, AzaC+TSA or both, showing no change in cell survival following either treatment (WOO7).
  • Results are presented as the mean absorbance at 450nm using the MTS survival assay ⁇ S.E.M of at least 3 replicates.
  • E- H No change in the amount of cells expressing annexinV following these treatments was observed (WOO4). Cell number is plotted as a function of the intensity of staining for annexin V.
  • FIGs. 9A-V are plots and graphs illustrating sorting of WT cells according to FZD7 surface expression is not reliable due both to receptor trafficking and its cellular localization.
  • E-T Receptor trafficking viewed by FACS at three sequential time points of incubation with the primary antibody - lhour, 2hours and 5hours.
  • E-L Incubation with anti-FZD7 antibody: upper and lower panels show opposite routes for FZD7 receptor trafficking, internalization - upper panel and re-expression - lower panel.
  • FIGs. 10A-H are graphs and photographs illustrating that FZD7 is a putative marker for the malignant renal stem cell containing population.
  • A-B Primary WTs and their derived xenografts were analyzed for the expression of FZD7 (A) and WTl (Bt) showing both to be significantly overexpressed by the blastemal enriched WT xenorafts in comparison to their primary source. Results are expressed as the mean ⁇ S.E.M of at least three different tumor sources and their xenografts; qRT-PCR for FZD7 expression
  • C Three of the separations according to the surface expression of FZD7 in WOO4 correlated to FZD7 mRNA expression.
  • Results are presented as the mean ⁇ S.E.M of three separate experiments demonstrating the FZD7(+) to be highly clonogenic compared to the FZD7(-) WT cells, * P ⁇ 0.05;
  • G Proliferation capacity of FZD7(+) and FZD7Q WT cells. 300 cells were plated in triplicates and the number of cells was counted by trypan blue staining on days 0, 3, 7, 14.
  • FIGs. HA-M are graphs and photograhs illustrating that NCAM + FZD7 + cell fraction may define stem-like cells in WT tumor
  • A-D Immunohistochemical staining for (A-B) NCAM and (C-D) FZD7 in WT shows that both are present in the malignant metanephric blastema (A and C) - magnification XlO.
  • NCAM stains immature tubular structures (B) - magnification X20, and FZD7, mature tubules (D) - magnification X40.
  • B-Blastema B-Blastema
  • IT- Immature Tubules MT-Mature Tubules
  • Separation of WOO4 cells according to NCAM and FZD7 surface expression E-F
  • E-F a negative cell fraction ( ⁇ 9%) (left panel) and an enriched positive cell fraction (>70%) (right panel).
  • G qRT-PCR analysis of NCAM expression in the NCAM + FZD7 + and NCAM ' cell fractions showing the double- positive population to highly express NCAM in comparison to the NCAM " cells
  • H-I Colony forming (CFU) assay shows that (H) NCAM + FZD7 + form more colonies in comparison to the NCAM " cells (I).
  • FIGs. 12A-B are cartoons illustrating the Wnt signaling pathway.
  • a cytoplasmic degradation complex consisting of at least axin, adenomatous polyposis coli (APC) protein, glycogen synthase kinase 3 (GSK-3), and ⁇ -catenin
  • APC adenomatous polyposis coli
  • GSK-3 glycogen synthase kinase 3
  • ⁇ -catenin leads to the phosphorylation of APC, ⁇ -catenin, and axin by GSK-3.
  • ⁇ -catenin is rapidly degraded in the cytoplasm.
  • nuclear levels of ⁇ -catenin are kept low by its interaction with APC and axin, both of which exist in the nucleus and have a nuclear export activity that shuttles ⁇ -catenin back to the cytoplasm.
  • Activation of the pathway is caused (right image) by interaction of secreted Wnts with transmembrane receptors encoded by the Frizzled gene family and with coreceptors such as low-density lipoprotein receptor- related protein-5 and -6 (LRP5 and 6).
  • the Wnt-Frizzled interaction is enhanced by some proteoglycans, such as the glypican-related protein Dally, and it is antagonized by several secreted proteins, including Dickkopf and secreted frizzled-related protein (sFRP) family members.
  • sFRP Dickkopf and secreted frizzled-related protein
  • Activation of Frizzled homologs by Wnt ligands leads to activation of the modular protein Dishevelled (DvI).
  • LRP5 or LRP6 may also activate the pathway in response to Wnts, although this mechanism is less clear.
  • DvI has been reported to interact directly with Frizzled and then function through binding components of the degradation complex to reduce the function of GSK-3.
  • the present invention in some embodiments thereof, relates to compositions and methods for treating cancer, specifically, pediatric cancers having embryonic stems cell origin, such as WiIm 's tumor.
  • WT Wilms tumor
  • FZD7 frizzled7
  • Figures IA-S the Ab induced cell death of the FZD7(+) fraction
  • Figures 4E-N the Ab induced cell death of the FZD7(+) fraction
  • Figures 5A-G the Ab induced cell death of the FZD7(+) fraction
  • FZD7-resistant WT in which no cell death was induced showed a different intra-cellular route of the Ab-FZD7 complex compared to sensitive tumors and accumulation of ⁇ -catenin ( Figures 3A- J).
  • the addition of exogenous DKKl and sFRPl to the tumor's cells enabled the sensitization of FZD7- resistant WT to the FZD7 Ab ( Figures 7A-R).
  • FZD7 antibody therapy alone or in combination with Wnt pathway antagonists may have a significant role in the treatment of WT via targeting of a tumor progenitor population.
  • a method of killing a cancer cell expressing NCAM and optionally FZD7 comprising contacting the cancer cell with a cytotoxic moiety and an NCAM targeting moiety (and optionally an FZD7 targeting moiety), thereby killing the cancer cell.
  • cancer refers to the physiological condition in mammals that is typically characterized by unregulated cell growth.
  • examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.
  • the cancer is a solid tumor (e.g., pediatric) having an embryonic stem cell origin.
  • solid tumors include, but are not limited to, sarcomas and carcinomas such as, but not limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile
  • pediatric solid tumors include but are not limited to: Wilms' tumor/Nephroblastoma, rhabdomyosarcoma, Ewing's family of tumors/primitive neuroectodermal tumor, Osteosarcoma, peripheral neuroectodermal tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, more specifically, Osteosarcoma, Rhabdomyosarcoma, Desmoplastic small round-cell tumor, Hepatoblastoma, Germ cell tumors, neuroblastoma and Medulloblastoma.
  • cancer cells which are contemplated for killing are those which express NCAM, FZD7 or both.
  • the method may also include determining the level of NCAM and/or FZD7 expression prior to treatment using methods which are well known in the art (such as described in the Examples section which follows).
  • NCAM refers to the gene product of the NCAM gene e.g., NM_181351, NM_000615, NM_001076682 (SEQ ID NOS: 1-3 respectively) NP_851996.2, NP_000606.3 AND NP_001070150.1 (SEQ ID NOS: 5-7 respectively).
  • FZD7 refers to the gene product of the FZD7 gene e.g., NM_003507 (SEQ ID NO: 4), NP_003498.1 (SEQ ID NO: 8).
  • the invention provides for a method of killing a cancer cell expressing FZD7 and optionally NCAM, the method comprising contacting the cancer cell with an FZD7 targeting moiety and an agent capable of inhibiting the Wnt pathway, thereby killing the cancer cell.
  • the method is effected by contacting the cell with an NCAM targeting moiety and an agent capable of Wnt pathway inhibition.
  • the method is effected by contacting the cell with an FZD7 targeting moiety, an NCAM targeting moiety and an agent capable of Wnt pathway inhibition.
  • targeting moiety refers to a molecule which specifically binds (i.e., sequence-specific binding or structure specific binding e.g., epitope dependent) a polypeptide or a nucleic acid sequence encoding same.
  • the targeting moiety may be an antibody or a peptide.
  • FZD7-targeting moiety refers to a targeting moiety specific to FZD7. It will be appreciated that the FZD7-targeting moiety may also be capable of downregulating activity or expression of FZD7, such as an antibody specific to FZD7.
  • An FZD7 activity refers not exclusively to a Wnt signaling activity.
  • NCAM-targeting moiety refers to a targeting moiety specific to NCAM.
  • An “agent capable of inhibiting the Wnt pathway” refers an antibody, a small molecule, a peptide, a polypeptide (e.g., antagonist such as DKKl and sFRPl) or a nucleic acid agent which is capable or down regulating activity or expression of at least one component of the Wnt signaling pathway (cannonical and non-cannonical).
  • a schematic illustration of the Wnt signaling pathway is provided in Figure 9. Each of the components illustrated (or those revealed during the term of this patent) is a putative target according to the present teachings.
  • composition of matter refers to a single component or a two-, three- or four- component compositions.
  • components include an NCAM targeting moiety, an FZD7 targeting moiety, an agent capable of inhibiting the Wnt pathway, a-cytetoxic moiety, a chemotherapeutic moiety and a radiotherapy as well as other active ingredients used as anti cancer treatments (e.g., antibody therapy, cytokine) or others such as Pseudomonas exotoxin, Diphteria exotoxin, interleukin 2, CD3, CD16, Interleukin 4, Interleukin 10, Ricin toxin and HLA-A2.
  • composition of matter may be packed in a packaging material wherein the components) are packed in a single or in separate containers.
  • composition of matter comprises a cytotoxic moiety and an NCAM targeting moiety.
  • composition of matter comprises a FZD7 targeting moiety and an agent capable of inhibiting the Wnt pathway.
  • the above mentioned components may be bound to each other by covalent or non-covalent binding or can be unbound.
  • the cytotoxic moiety and/or the agent capable of inhibiting the Wnt pathway may be comprised in an encapsulating particle and the NCAM and/or FZD7 targeting moiety may be attached to the particle surface.
  • the phrase "encapsulating particle” refers to an entity that is characterized by the presence of one or more walls or membranes formulated from lipids and/or fatty acids that form one or more internal voids.
  • the walls or membranes may be concentric or otherwise.
  • the walls or membranes of vesicles may be substantially solid (uniform), or referred to as, for example, liposomes, lipospheres, nanoliposomes, particles, micelles, bubbles, microbubbles, microspheres, nanospheres, nanostructures, microballoons, microcapsules, aerogels, clathrate bound vesicles, hexagonal/cubic/hexagonal II phase structures, and the like.
  • the lipid component included in the encapsulating particles could include either a lipid derivatized with the targeting molecule, or a lipid having a polar-head chemical group that can be derivatized with the targeting molecule in preformed particles, according to known methods.
  • Downregulation of FZD7 or Wnt can be effected on the genomic and/or the transcript level using a variety of molecules which interfere with transcription and/or translation (e.g., RNA silencing agents, Ribozyme, DNAzyme and antisense), or on the protein level using e.g., antagonists, enzymes that cleave the polypeptide and the like.
  • RNA silencing agents e.g., Ribozyme, DNAzyme and antisense
  • an agent capable of downregulating FZD7 or Wnt is an antibody or antibody fragment capable of specifically binding FZD7 or a Wnt pathway component.
  • epitopic determinants refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • antibody as used in this invention includes intact molecules as well as functional fragments thereof, such as Fab, F(ab*)2, and Fv that are capable of binding to macrophages.
  • These functional antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab 1 , the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab ⁇ 2, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab')2 is a dimer of two Fab' fragments held together by two disulfide bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region
  • Antibody fragments according to the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment.
  • Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods.
  • antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')2.
  • This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments.
  • an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly.
  • These methods are described, for example, by Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. R. [Biochem. J. 73: 119-126 (1959)].
  • Other methods of cleaving antibodies such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.
  • Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar et al. [Proc. Natl Acad. Sci. USA 69:2659-62 (1972O]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker.
  • sFv single-chain antigen binding proteins
  • the structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli.
  • the recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains.
  • Methods for producing sFvs are described, for example, by [Whitlow and Filpula, Methods 2: 97- 105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.
  • the antibody is a bispecific antibody, an antibody molecule which is designed to bind to two different antigens (e.g., NCAM and FZD7).
  • bispecific antibodies and methods of generating same are known in the art see e.g., 7,537,931, which is hereby incorporated by reference.
  • CDR peptides (“minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry [Methods, 2: 106-10 (1991)].
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab').sub.2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • CDR complementary determining region
  • donor antibody such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].
  • Fc immunoglobulin constant region
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
  • humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. MoI. Biol., 227:381 (1991); Marks et al., J. MoI. Biol., 222:581 (1991)].
  • the techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(l):86-95 (1991)].
  • human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos.
  • Non-limiting examples of therapeutic moieties which can be conjugated to the antibody of embodiments of the present invention are provided in Table 1, hereinbelow.
  • the toxic moiety is PE38KDEL.
  • the therapeutic moiety may be attached or conjugated to the antibody of embodiments of the invention in various ways, depending on the context, application and purpose.
  • the immunoconjugate may be produced by recombinant means.
  • the nucleic acid sequence encoding a toxin e.g., PE38KDEL
  • the functional moiety may be chemically synthesized by, for example, the stepwise addition of one or more amino acid residues in defined order such as solid phase peptide synthetic techniques.
  • a therapeutic moiety may also be attached to the antibody of the invention using standard chemical synthesis techniques widely practiced in the art [see e.g., hypertexttransferprotocol://worldwideweb (dot) chemistry (dot) org/portal/Chemistry)], such as using any suitable chemical linkage, direct or indirect, as via a peptide bond (when the functional moiety is a polypeptide), or via covalent bonding to an intervening linker element, such as a linker peptide or other chemical moiety, such as an organic polymer.
  • Chimeric peptides may be linked via bonding at the carboxy (C) or amino (N) termini of the peptides, or via bonding to internal chemical groups such as straight, branched or cyclic side chains, internal carbon or nitrogen atoms, and the like.
  • Description of fluorescent labeling of antibodies is provided in details in U.S. Pat. Nos. 3,940,475, 4,289,747, and 4,376,110.
  • SPDP conjugation A non-limiting example of a method of SPDP conjugation is described in Cumber et al. (1985, Methods of Enzymology 112: 207-224). Briefly, a peptide, such as a detectable or therapeutic moiety (e.g., 1.7 mg/ml) is mixed with a 10- fold excess of SPDP (50 mM in ethanol); the antibody is mixed with a 25-fold excess of SPDP in 20 mM sodium phosphate, 0.10 M NaCl pH 7.2 and each of the reactions is incubated for about 3 hours at room temperature. The reactions are then dialyzed against PBS.
  • a detectable or therapeutic moiety e.g., 1.7 mg/ml
  • SPDP a detectable or therapeutic moiety
  • the antibody is mixed with a 25-fold excess of SPDP in 20 mM sodium phosphate, 0.10 M NaCl pH 7.2 and each of the reactions is incubated for about 3 hours at room temperature. The reactions are then dialyzed
  • the peptide is reduced, e.g., with 50 mM DTT for 1 hour at room temperature.
  • the reduced peptide is desalted by equilibration on G-25 column (up to 5 % sample/column volume) with 50 mM KH 2 PO 4 pH 6.5.
  • the reduced peptide is combined with the SPDP-antibody in a molar ratio of 1:10 antibody :peptide and incubated at 4 °C overnight to form a peptide-antibody conjugate.
  • Glutaraldehyde conjugation A non-limiting example of a method of glutaraldehyde conjugation is described in G.T. Hermanson (1996, “Antibody Modification and Conjugation, in Bioconjugate Techniques, Academic Press, San Diego). Briefly, the antibody and the peptide (1.1 mg/ml) are mixed at a 10-fold excess with 0.05 % glutaraldehyde in 0.1 M phosphate, 0.15 M NaCl pH 6.8, and allowed to react for 2 hours at room temperature. 0.01 M lysine can be added to block excess sites. After-the reaction, the excess glutaraldehyde is removed using a G-25 column equilibrated with PBS (10 % v/v sample/column volumes)
  • Carbodiimide conjugation - Conjugation of a peptide with an antibody can be accomplished using a dehydrating agent such as a carbodiimide, e.g., in the presence of 4-dimethyl aminopyridine.
  • Carbodiimide conjugation can be used to form a covalent bond between a carboxyl group of peptide and an hydroxyl group of an antibody (resulting in the formation of an ester bond), or an amino group of an antibody (resulting in the formation of an amide bond) or a sulfhydryl group of an antibody (resulting in the formation of a thioester bond).
  • carbodiimide coupling can be used to form analogous covalent bonds between a carbon group of an antibody and an hydroxyl, amino or sulfhydryl group of the peptide [see, J. March, Advanced Organic Chemistry: Reaction's, Mechanism, and Structure, pp. 349-50 & 372-74 (3d ed.), 1985].
  • the peptide can be conjugated to an antibody via a covalent bond using a carbodiimide, such as dicyclohexylcarbodiimide [B. Neises et al. (1978), Angew Chem., Int. Ed. Engl. 17:522; A. Hassner et al. (1978, Tetrahedron Lett. 4475); E.P. Boden et al. (1986, J. Org. Chem. 50:2394) and LJ. Mathias (1979, Synthesis 561)].
  • RNA silencing refers to a group of regulatory mechanisms [e.g. RNA interference (RNAi), transcriptional gene silencing (TGS), post-transcriptional gene silencing (PTGS), quelling, co- suppression, and translational repression] mediated by RNA molecules which result in the inhibition or "silencing" of the expression of a corresponding protein-coding gene. RNA silencing has been observed in many types of organisms, including plants, animals, and fungi.
  • RNA silencing agent refers to an RNA which is capable of inhibiting or “silencing" the expression of a target gene.
  • the RNA silencing agent is capable of preventing complete processing (e.g, the full translation and/or expression) of an mRNA molecule through a post- transcriptional silencing mechanism.
  • RNA silencing agents include noncoding RNA molecules, for example RNA duplexes comprising paired strands, as well as precursor RNAs from which such small non-coding RNAs can be generated.
  • Exemplary RNA silencing agents include dsRNAs such as siRNAs, miRNAs and shRNAs.
  • the RNA silencing agent is capable of inducing RNA interference.
  • the RNA silencing agent is capable of mediating translational repression.
  • RNA interference refers to the process of sequence-specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs).
  • siRNAs short interfering RNAs
  • the corresponding process in plants is commonly referred to as post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi.
  • the process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes and is commonly shared by diverse flora and phyla.
  • Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or from the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA.
  • dsRNAs double-stranded RNAs
  • the presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as dicer.
  • Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs).
  • Short interfering RNAs derived from dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes.
  • RNAi response also features an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex.
  • RISC RNA-induced silencing complex
  • the present invention contemplates use of dsRNA to downregulate protein expression from mRNA.
  • the dsRNA is greater than 30 bp.
  • the use of long dsRNAs i.e. dsRNA greater than 30 bp
  • the use of long dsRNAs can provide numerous advantages in that the cell can select the optimal silencing sequence alleviating the need to test numerous siRNAs; long dsRNAs will allow for silencing libraries to have less complexity than would be necessary for siRNAs; and, perhaps most importantly, long dsRNA could prevent viral escape mutations when used as therapeutics.
  • the present invention also contemplates introduction of long dsRNA (over 30 base transcripts) for gene silencing in cells where the interferon pathway is not activated (e.g. embryonic cells and oocytes) see for example Billy et al., PNAS 2001, VoI 98, pages 14428-14433. and Diallo et al, Oligonucleotides, October 1, 2003, 13(5): 381-392. doi:10.1089/154545703322617069.
  • the present invention also contemplates introduction of long dsRNA specifically designed not to induce the interferon and PKR pathways for down- regulating gene expression. For example, Shinagwa and Ishii [Genes &. Dev.
  • pDECAP RNA polymerase II
  • siRNAs small inhibitory RNAs
  • siRNA refers to small inhibitory RNA duplexes (generally between 18-30 basepairs) that induce the RNA interference (RNAi) pathway.
  • RNAi RNA interference
  • siRNAs are chemically synthesized as 21mers with a central 19 bp duplex region and symmetric 2-base 3 '-overhangs on the termini, although it has been recently described that chemically synthesized RNA duplexes of 25-30 base length can have as much as a 100- fold increase in potency compared with 21mers at the same location.
  • RNA silencing agent of the present invention may also be a short hairpin RNA (shRNA).
  • RNA agent refers to an RNA agent having a stem-loop structure, comprising a first and second region of complementary sequence, the degree of complementarity and orientation of the regions being sufficient such that base pairing occurs between the regions, the first and second regions being joined by a loop region, the loop resulting from a lack of base pairing between nucleotides (or nucleotide analogs) within the loop region.
  • the number of nucleotides in the loop is a number between and including 3 to 23, or 5 to 15, or 7 to 13, or 4 to 9, or 9 to 11. Some of the nucleotides in the loop can be involved in base-pair interactions with other nucleotides in the loop.
  • the RNA silencing agent may be a miRNA.
  • miRNAs are small RNAs made from genes encoding primary transcripts of various sizes. They have been identified in both animals and plants.
  • the primary transcript (termed the "pri-miRNA") is processed through various nucleolytic steps to a shorter precursor miRNA, or "pre -miRNA.”
  • the pre-miRNA is present in a folded form so that the final (mature) miRNA is present in a duplex, the two strands being referred to as the miRNA (the strand that will eventually basepair with the target)
  • the pre-miRNA is a substrate for a form of dicer that removes the miRNA duplex from the precursor, after which, similarly to siRNAs, the duplex can be taken into the RISC complex.
  • miRNAs can be transgenically expressed and be effective through expression of a precursor form, rather than the entire primary form (Parizotto et al. (2004) Genes & Development 18:2237-2242 and Guo et al. (2005) Plant Cell 17:1376- 1386).
  • miRNAs bind to transcript sequences with only partial complementarity (Zeng et al., 2002, Molec. Cell 9:1327-1333) and repress translation without affecting steady-state RNA levels (Lee et al., 1993, Cell 75:843-854; Wightman et al., 1993, Cell 75:855-862). Both miRNAs and siRNAs are processed by Dicer and associate with components of the RNA-induced silencing complex (Hutvagner et al., 2001, Science 293:834-838; Grishok et al., 2001, Cell 106: 23-34; Ketting et al., 2001, Genes Dev.
  • RNA silencing agents suitable for use with the present invention can be effected as follows. First, the FZD7 or Wnt pathway component (e.g., beta- catenin) mRNA sequence is scanned downstream of the AUG start codon for AA dinucleotide sequences. Occurrence of each AA and the 3' adjacent 19 nucleotides is recorded as potential siRNA target sites. Preferably, siRNA target sites are selected from the open reading frame, as untranslated regions (UTRs) are richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNA endonuclease complex [Tuschl ChemBiochem. 2:239-245].
  • UTRs untranslated regions
  • siRNAs directed at untranslated regions may also be effective, as demonstrated for GAPDH wherein siRNA directed at the 5' UTR mediated about 90 % decrease in cellular GAPDH mRNA and completely abolished protein level (www.ambion.com/techlib/tn/91/912.html).
  • potential target sites are compared to an appropriate genomic database (e.g., human, mouse, rat etc.)- using any sequence alignment software, such as the BLAST software available from the NCBI server (www.ncbi.nlm.nih.gov/BLAST/). Putative target sites which exhibit significant homology to other coding sequences are filtered out.
  • an appropriate genomic database e.g., human, mouse, rat etc.
  • sequence alignment software such as the BLAST software available from the NCBI server (www.ncbi.nlm.nih.gov/BLAST/).
  • Qualifying target sequences are selected as template for siRNA synthesis.
  • Preferred sequences are those including low G/C content as these have proven to be more effective in mediating gene silencing as compared to those with G/C content higher than 55 %.
  • Several target sites are preferably selected along the length of the target gene for evaluation.
  • a negative control is preferably used in conjunction.
  • Negative control siRNA preferably include the same nucleotide composition as the siRNAs but lack significant homology to the genome.
  • a scrambled nucleotide sequence of the siRNA is preferably used, provided it does not display any significant homology to any other gene.
  • the RNA silencing agent of the present invention need not be limited to those molecules containing only RNA, but further encompasses chemically-modified nucleotides and non-nucleotides.
  • the RNA silencing agent provided herein can be functionally associated with a cell -penetrating peptide.
  • a "cell- penetrating peptide” is a peptide that comprises a short (about 12-30 residues) amino acid sequence or functional motif that confers the energy-independent (i.e., non- endocytotic) translocation properties associated with transport of the membrane- permeable complex across the plasma and/or nuclear membranes of a cell.
  • the cell- penetrating peptide used in the membrane-permeable complex of the present invention preferably comprises at least one non-functional cysteine residue, which is either free or derivatized to form a disulfide link with a double-stranded ribonucleic acid that has been modified for such linkage.
  • Representative amino acid motifs conferring such properties are listed in U.S. Pat. No. 6,348,185, the contents of which are expressly incorporated herein by reference.
  • the cell-penetrating peptides of the present invention preferably include, but are not limited to, penetratin, transportan, plsl, TAT(48-60), pVEC, MTS, and MAP.
  • RNA silencing agents include, but are not limited to, those whose expression is correlated with an undesired phenotypic trait.
  • Exemplary mRNAs that may be targeted are those that encode truncated proteins i.e. comprise deletions. Accordingly the RNA silencing agent of the present invention may be targeted to a bridging region on either side of the deletion. Introduction of such RNA silencing agents into a cell would cause a down-regulation of the mutated protein while leaving the non-mutated protein unaffected.
  • Cancer-related genes include oncogenes (e.g., K-ras, c-myc, bcr/abl, c-myb, c- fms, c-fos and cerb-B), growth factor genes (e.g., genes encoding epidermal growth factor and its receptor, fibroblast growth factor-binding protein), matrix metalloproteinase genes (e.g., the gene encoding MMP-9), adhesion-molecule genes (e.g., the gene encoding VLA-6 integrin), tumor suppressor genes (e.g., bcl-2 and bcl- Xl), angiogenesis genes, and metastatic genes.
  • oncogenes e.g., K-ras, c-myc, bcr/abl, c-myb, c- fms, c-fos and cerb-B
  • growth factor genes e.g., genes encoding epidermal growth
  • Rheumatoid arthritis-related genes include, for example, genes encoding stromelysin and tumor necrosis factor.
  • Viral genes include human papilloma virus genes (related, for example, to cervical cancer), hepatitis B and C genes, and cytomegalovirus (CMV) genes (related, for example, to retinitis). Numerous other genes relating to these diseases or others might also be targeted.
  • DNAzyme molecule capable of specifically cleaving an mRNA transcript or DNA sequence of the Wnt pathway member.
  • DNAzymes are single-stranded polynucleotides which are capable of cleaving both single and double stranded target sequences (Breaker, R.R. and Joyce, G. Chemistry and Biology 1995;2:655; Santoro, S.W. & Joyce, G.F. Proc. Natl, Acad. Sci. USA 1997;943:4262)
  • a general model (the "10-23" model) for the DNAzyme has been proposed.
  • DNAzymes have a catalytic domain of 15 deoxyribonucleotides, flanked by two substrate-recognition domains of seven to nine deoxyribonucleotides each.
  • This type of DNAzyme can effectively cleave its substrate RNA at purine :pyrimidine junctions (Santoro, S.W. & Joyce, G.F. Proc. Natl, Acad. Sci. USA 199; for rev of DNAzymes see Khachigian, LM [Curr Opin MoI Ther 4:119- 21 (2002)].
  • DNAzymes recognizing single and double-stranded target cleavage sites have been disclosed in U.S. Pat. No. 6,326,174 to Joyce et al. DNAzymes of similar design directed against the human Urokinase receptor were recently observed to inhibit Urokinase receptor expression, and successfully inhibit colon cancer cell metastasis in vivo (Itoh et al , 20002, Abstract 409, Ann Meeting Am Soc Gen Ther www.asgt.org). In another application, DNAzymes complementary to bcr-abl oncogenes were successful in inhibiting the oncogenes expression in leukemia cells, and lessening relapse rates in autologous bone marrow transplant in cases of CML and ALL.
  • Downregulation of a Wnt pathway can also be effected by using an antisense polynucleotide capable of specifically hybridizing with an mRNA transcript encoding same.
  • the first aspect is delivery of the oligonucleotide into the cytoplasm of the appropriate cells, while the second aspect is design of an oligonucleotide which specifically binds the designated mRNA within cells in a way which inhibits translation thereof.
  • antisense oligonucleotides suitable for the treatment of cancer have been successfully used [Holmund et al., Curr Opin MoI Ther 1:372-85 (1999)], while treatment of hematological malignancies via antisense oligonucleotides targeting c-myb gene, p53 and Bcl-2 had entered clinical trials and had been shown to be tolerated by patients [Gerwitz Curr Opin MoI Ther 1:297-306 (1999)].
  • antisense-mediated suppression of human heparanase gene expression has been reported to inhibit pleural dissemination of human cancer cells in a mouse model [Uno et al., Cancer Res 61:7855-60 (2001)].
  • Another agent capable of downregulating a Wnt pathway member is a ribozyme molecule capable of specifically cleaving an mRNA transcript encoding a the wnt gene.
  • Ribozymes are being increasingly used for the sequence-specific inhibition of gene expression by the cleavage of mRNAs encoding proteins of interest [Welch et al., Curr Opin Biotechnol. 9:486-96 (1998)].
  • the possibility of designing ribozymes to cleave any specific target RNA has rendered them valuable tools in both basic research and therapeutic applications.
  • ribozymes have been exploited to target viral RNAs in infectious diseases, dominant oncogenes in cancers and specific somatic mutations in genetic disorders [Welch et al., Clin Diagn Virol. 10:163-71 (1998)]. Most notably, several ribozyme gene therapy protocols for HIV patients are already in Phase 1 trials. More recently, ribozymes have been used for transgenic animal research, gene target validation and pathway elucidation. Several ribozymes are in various stages of clinical trials. ANGIOZYME was the first chemically synthesized ribozyme to be studied in human clinical trials.
  • ANGIOZYME specifically inhibits formation of the VEGF-r (Vascular Endothelial Growth Factor receptor), a key component in the angiogenesis pathway.
  • Ribozyme Pharmaceuticals, Inc. as well as other firms have demonstrated the importance of anti-angiogenesis therapeutics in animal models.
  • HEPTAZYME a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was found effective in decreasing Hepatitis C viral RNA in cell culture assays (Ribozyme Pharmaceuticals, Incorporated - WEB home page).
  • Another agent capable of downregulating Wnt would be any molecule which upregulates endogenous expression of Wnt antegonists such as demethylating agents as described in the examples section.
  • the level of Wnt antagonists can be elevated exogenously by the addition of those antagonists
  • Demethylating agents are compounds that can inhibit methylation, resulting in the expression of the previously hypermethylated silenced genes (see methylation: methylation and cancer for more detail).
  • Cytidine analogs such as 5-azacytidine (azacitidine) and 5-azadeoxycytidine (decitabine) are the most commonly used demethylating agents. These compounds work by binding to the enzymes that catalyse the methylation reaction, DNA methyltransferases; and titrate out these enzymes. Both compounds have been approved for treatment by Food and Drug Administration (FDA) in United States. Azacitidine and decitabine are marketed as Vidaza® and Dacogen® respectively.
  • compositions described herein to kill cancer cells prompts their use in treating cancer in a subject in need thereof.
  • treating refers to inhibiting, preventing or arresting the development of a pathology (disease, disorder or condition) and/or causing the reduction, remission, or regression of a pathology.
  • pathology disease, disorder or condition
  • Those of skill in the art will understand that various methodologies and assays can be used to assess the development of a pathology, and similarly, various methodologies and assays may be used to assess the reduction, remission or regression of a pathology.
  • the term "preventing” refers to keeping a disease, disorder or condition from occurring in a subject who may be at risk for the disease, but has not yet been diagnosed as having the disease.
  • the term "subject” includes mammals, preferably human beings at any age which suffer from the pathology. Preferably, this term encompasses individuals who are at risk to develop the pathology.
  • Each of downregulating agents described hereinabove compositions can be administered to the individual per se or as part of a pharmaceutical composition which also includes a physiologically acceptable carrier.
  • the purpose of a pharmaceutical composition is to facilitate administration of the active ingredient to an organism.
  • a pharmaceutical composition refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
  • active ingredient refers to the component (e.g., FZD7 targeting moiety, Wnt inhibitor, NKAM targeting moiety, cytotoxic moiety, radiotherapy) accountable for the biological effect.
  • physiologically acceptable carrier and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
  • An adjuvant is included under these phrases.
  • excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
  • excipients examples include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
  • Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, inrtaperitoneal, intranasal, or intraocular injections.
  • neurosurgical strategies e.g., intracerebral injection or intracerebroventricular infusion
  • molecular manipulation of the agent e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the
  • BBB BBB in an attempt to exploit one of the endogenous transport pathways of the BBB
  • pharmacological strategies designed to increase the lipid solubility of an agent e.g., conjugation of water-soluble agents to lipid or cholesterol carriers
  • the transitory disruption of the integrity of the BBB by hyperosmotic disruption resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide.
  • each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.
  • compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
  • physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
  • Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient.
  • Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions which can be used orally include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • compositions described herein may be formulated for parenteral administration, e.g., by bolus injection or continuos infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative.
  • the compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
  • a suitable vehicle e.g., sterile, pyrogen-free water based solution
  • compositions of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
  • compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of a disorder or prolong the survival of the subject being treated.
  • the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays.
  • a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
  • Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.l).
  • Dosage amount and interval may be adjusted individually to provide levels of the active ingredient are sufficient to induce or suppress the biological effect (minimal effective concentration, MEC).
  • MEC minimum effective concentration
  • the MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
  • dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
  • compositions to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
  • compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may, for example, comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • the pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
  • Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.
  • composition or method may include additional ingredients and/or steps, but only if the additional ingredients and/or steps do not materially alter the basic and novel characteristics of the claimed composition or method.
  • a compound or “at least one compound” may include a plurality of compounds, including mixtures thereof.
  • range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
  • method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
  • telomeres WT cells using Qiagen DNA Extraction Kit according to the manufacturer instructions.
  • the entire coding regions and splice sites were PCR amplified using Ready-To-Go PCR Beads (Amersham Pharmacia Biotech) and lOpmol of primer in a total volume of 25 ⁇ l.
  • the amplification conditions included initial denaturation at 96 0 C for 4 minutes, 35 cycles at 94 °C for 1 min, annealing at Tm temperature for 45 sec, and 72 0 C for 1 min followed by a 10 min extension step at 72 0 C.
  • PCR Primers for the CTNNBl gene were designed based on accession number NT 022517.
  • PCR products were purified using Geneclean® Spin Kit (Qbiogene) and automated sequencing was performed on an ABI PRISM 3100 Genetic Analyzer using BigDye Terminator Cycle Sequencing Kit according to the manufacturer's protocol (Applied Biosystems).
  • CTNNBl and WTX sequence analysis was done by comparing the sequence data obtained to the CTNNBl gene sequence (accession number NT_022517 and NM_152424 respectively) using NCBI-BLAST (httpblastdotncbidotnlmdotnihdotgovBlastdotcgi).
  • qPCR quantitative polymerase chain reaction
  • GAPDH was used as endogenous control throughout all experimental analyses. Gene expression analysis was performed using TaqMan Gene Expression Assays on an ABI Prism 7900HT sequence detection system (Applied Biosystems, Foster City, California, USA). AzaC and TSA treatment of primary WT cell cultures: Cells were seeded at a density of 10 5 cells/25T flask on day 0. 24h after seeding, the demethylating agents AzaC and the de-acetylase inhibitor (HDAC inhibitor) TSA (Sigma-Aldrich, Steinheim, Germany) were added to a final concentration of 50 ⁇ M and 250 nM in fresh medium, respectively.
  • HDAC inhibitor de-acetylase inhibitor
  • Control cells were incubated with the addition of the same volumes of the solvents used for the AzaC and TSA - ETOH and Acetic acid respectively in fresh medium. 24 hours later, cells were harvested from both treated and control flasks for RNA extraction and cDNA production. !
  • Fluorescence-activated cell sorting (FACS) analysis FACS analysis was performed as previously described (Pode-Shakked et al, 2008). For analysis of FZD7, CD133 and NCAM expression in different time points, cells were harvested using non enzymatic cell dissociation solution (Sigma-Aldrich, St. Louis). Surface antigens were labeled by incubation with either fluorochrome conjugated— CD133:PE (Miltenyi biotech) and NCAMrAPC (eBioscience, San Diego, CA) or biotin conjugated - anti FZD7 (R&D systems), primary antibodies, for 45 minutes in the dark at 4°C to prevent internalization of antibodies.
  • fluorochrome conjugated CD133:PE (Miltenyi biotech) and NCAMrAPC (eBioscience, San Diego, CA)
  • biotin conjugated - anti FZD7 R&D systems
  • the cells were incubated for 20-30 minutes with the strepavidin APC in addition to 7-amino-actinomycin-D (7AAD; eBioscience, San Diego, CA) for viable cell gating.
  • Staining with strep-aviding APC was then performed on additional samples after 2h and 5h to minimize signal downregulation due to bleaching. Staining was performed in FACS buffer consisting of 0.5% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis) and 0.02% sodium azide in PBS and all washing steps were performed in buffer consisting of 0.1%BSA in PBS. Quantitative measurements were made from the cross point of the IgG isotype graph with the specific antibody graph. Data were additionally analyzed and presented using FlowJo software (Tree Star, Ashland, OR).
  • Immunofluorescence staining for FZD7 receptor WOO4 cells (10 5 cells/mL) were grown on 12-mm round glass coverslips. For immunofluorescence processing, cells were washed twice with PBS and fixed for 10 minutes at room temperature in 4 % paraformaldehyde/PBS. Cells were subsequently washed 3 times with PBS and permeabilized for 5 minutes with PBS, 1 % BSA and 0.5 % Triton X-100.
  • FZD7 Antibody uptake - WOO4 and WOlO cells were incubated with monoclonal anti FZD7 antibodies (1.5 ⁇ g/100 ⁇ 1 or coverslip) for 60 minutes on ice, washed 3 times in PBS and followed by incubation at 37 0 C for the indicated time periods to allow internalization [Haberman et al, 2007]. Cells were washed in PBS, fixed for 10 minutes at room temperature in 4% paraformaldehyde/PBS and were subsequently processed as indicated above.
  • Annexin-V staining kit eBioscience, San Diego, CA
  • Annexin V binds to phosphotidyl-serines normally found in the cytoplasmic surface of the cell membrane but can be found on the outer aspect of the cell membrane in apoptotic cells.
  • Annexin V binds to phosphotidyl-serines normally found in the cytoplasmic surface of the cell membrane but can be found on the outer aspect of the cell membrane in apoptotic cells.
  • necrosis and late apoptosis membrane integrity is compromised, and cells are stained by both Annexin V and 7AAD; Cells were treated with 0.1 mg/ml of anti-FZD7 antibody with respect to untreated control. Both samples were kept at 4 0 C for 12 h.
  • Annexin V binding buffer eBiocience
  • 5 ⁇ l of either fluoroscein isothiocyanate (FITC) or Allophecoaritin (APC)-conjugated annexin V was added to the samples and/or controls followed by incubation for 15 min at room temperature in the dark.
  • Annexin V binding was evaluated by using FACSria (Becton Dickinson) with CELLQUEST software (BD Biosciences).
  • FZD7-sensitive and -resistant WT cells were washed with PBS, resuspended at 1 x 10 6 cell/ml in PBS/BSA 0.1 %, and then either incubated with anti-FZD7 Ab or with the same amount of Ab diluent for 4 hours.
  • Nephroblastoma cells were plated in 96 well plates at 5xlO 3 cells/well in culture medium and treated with 0.1 ⁇ g/ ⁇ l of anti FZD7 antibody or with 250 ⁇ g/ml of AzaC or with a combination of both, in respect to untreated controls for 48h.
  • the viability was assessed by the addition of the novel tetrazolium compound (3-[4,5-dimethylthiazol-2-yl-5]-[3-carboxymethyoxyphenyl]-2- [4-sulfophenyl]-2H tetrazolium) MTS (Promega, Madison, WI) for 4 hours, followed by measuring absorbance at 450 nm on an enzyme-linked immunosorbent assay (ELISA) microplate reader.
  • novel tetrazolium compound 3-[4,5-dimethylthiazol-2-yl-5]-[3-carboxymethyoxyphenyl]-2- [4-sulfophenyl]-2H tetrazolium
  • MTS Promega, Madison, WI
  • ELISA enzyme-linked immunosorbent assay
  • Immunofluorescence staining for ⁇ -catenin Cells were collected from 6 well plates after 5 minutes of Trypsin Digestion. Cells were washed and plated on glass slides for 5 hours or over night. Slides were fixed using cold acetone and then air dried. Cells were washed three times with PBS and blocked with 7 % horse serum. Primary anti Human ⁇ - catenin (Millipore corp.) was added at a 1:150 dilution for 60 min. Following staining the slides were washed three times with PBS and anti mouse alexafluor 568 (Molecular Probes INC. Invitrogen) was applied at 1:200 dilution for 30 min. After the final washes cover slips were mounted and put on the slide. Images were taken using the ZEISS ApoTome grid system. Breast epithelial cells and human fibroblasts were used as positive and negative control respectively.
  • Limiting dilution assay was performed as previously described [Pode-Shakked et al 2008; Tropepe et al., 1999].
  • WT tumor cells were sorted according to FZD7 expression and the sorted cell fractions were plated in 96-well micro well plates (Greiner Bio-One, Mediscan, Kremsmunster, Austria) in 150 ⁇ l of culture media, at 0.3 or 1 cells per well dilution. The low cell concentration was achieved by serial dilutions reaching 1000 cells per ml. The number of colonized wells was recorded after 4 weeks.
  • Trypan blue proliferation assay After sorting of FZD7-resistant WT cells according to FZD7 expression, positive and negative cells were seeded at the same density of 10 3 cells/well in 96-well plates in triplicates on day 0. On days 1, 3, 7, 14 cells from three wells were harvested and suspended in medium, separately for each well. Subsequently, an aliquot of cell suspension from each well was diluted with 0.4 % trypan blue (Sigma-Aldrich), pipetted onto a haemocytemeter and counted under a microscope at 10x magnification. Live cells excluded the dye, whereas dead cells admitted the dye and consequently stained intensely with trypan blue. Counts were done in triplicates for each well and three wells for each time points were used. Proliferation was evaluated by comparing the number of viable FZD7+ with the number of viable FZD7- WT cells in 5 time points over 21 days.
  • Immunohistochemical staining of WT Sections, 4- ⁇ m thick, were cut from whole blocks of human fetal kidney from 20 weeks of gestation, human adult kidney and WT for immunohistochemistry. Immunostainings were performed as previously described [Dekel et al, 2006b ;Pode Shakked et al, 2008]. In brief, the sections were processed within 1 week to avoid oxidation of antigens. Before immunostaining, sections were treated with 1OmM citrate buffer, PH 6.0 for 10 min at 97°C in a microwave oven for antigen retrieval, followed by treatment of 3% H 2 O 2 for 10 min.
  • the slides were subsequently stained by the labeled strepavidin-biotin (LAB-SA) method using a Histostain plus kit (Zymed, San Francisco, CA, USA).
  • Anti human FZD7 antibody Novus biological
  • Controls were prepared by omitting the primary antibodies or by substituting the primary antibodies with goat IgG isotype.
  • the immunoreaction was visualized by an HRP-based chromogen/substrate system, including DAB (brown) chromogen (liquid DAB substrate kit - Zymed, San Francisco, CA, USA).
  • Sphere forming assay Cells from FZD7 resistant and sensitive WTs were either treated with 0.5mg/ml per 10 6 cells of anti FZD7 Ab or with the Ab solvent for 4h. Following incubation cells were plated in ultra low attachment six -well plates (Corning Life Sciences, Wilkes Barre, PA, USA) at 20,000 cells/well in serum-free DMEM-F12 (Invitrogen), supplemented with 10 ng/mL basic fibroblast growth factor (bFGF) and 20ng/mL Epidermal grot factor (EGF). Spheres were recorded and counted after incubation for 7 days at 37 ° C, 5% CO 2 .
  • bFGF basic fibroblast growth factor
  • EGF Epidermal grot factor
  • Colony forming assay FZD7 resistant and sensitive WT cells either treated or untreated with anti FZD7 Ab were plated in growth medium on matrigel coated 12 well plates at 2500 cells/well, in duplicates. NCAM + FZD7 + and NCAM " WT sorted cells were plated in growth medium on matrigel coated 12 well plates at 25000 cells/well dilution in duplicates. Medium was changed twice a week. Colonies were recorded after two weeks and both their number and the number of cells/colonies were counted. The mean colony number and the mean number of cells in each colony for each cell fraction were calculated from the sum of all triplicates.
  • CAM chick embryo chorioallantoic membrane
  • Double-immunocytochemistry for Ki67 (mammalian-specific monoclonal rabbit antibody, Lab Vision clone SP6) and NCAM (mouse monoclonal, Santa Cruz) was performed on the sections containing WT cells using microwave antigen retrieval. Detection was performed with Alexa-488 anti- mouse and Alexa-594 anti-rabbit antibodies (Molecular Probes), and slides were counterstained with Hoechst, and all serial sections were examined. Photomicrographs were made with digital cameras (CFW-1312M and CFW-1612C, Scion Corporation) on Olympus SZX12 and BX51 microscopes. Confocal images were made with an Olympus Fluoview 2000 using 3 lasers and sequential acquisition of fluorophores.
  • a Z-series of 7 optical slices was made of a field, and the in-focus portions of each channel image combined into a single image using the "extended depth of field" plugin of ImageJ (httprsbwebdotnihdotgovij). All changes in the images (contrast, brightness, gamma, sharpening) were made evenly across the entire field, and no features were removed or added digitally
  • Figures IJ-L shows the percentage of dead cells following treatment with the Ab is not elevated, and therefore there is no correlation with the 20.6 % of cells that express FZD7 receptor on their surface.
  • Figures IP-R, W002 there was only a weak response to application of the anti-FZD7 antibody.
  • the percentage of dead cells (Annexin V + ) was significantly lower ( ⁇ 3%) than the number of cells expressing FZD7 (>15%) in this tumor.
  • a FACS-based killing assay on FZD7 sensitive and resistant WTs revealed that higher anti-FZD7 concentrations induced significant cell death exclusively in the sensitive tumors ( Figures IS and 2A-H) Moreover, percentage of cell death in the sensitive tumor at the highest anti FZD7 concentration (150 ⁇ g/ml) correlated with the percentage of cells expressing FZD7 on their surface ( Figures 2I-J). Taken together these findings support both the anti-FZD7 Ab killing effect in a subset of WTs and its specificity for WT cells expressing the FZD7 receptor.
  • FZD7(+) cells from FZD7-sensitive WT cannot be prospectively isolated in order to evaluate this cell fraction for stem/progenitor characteristics.
  • the present inventors therefore asked whether application of the FZD7 Ab to FZD7-sensitive WT cultures and specific elimination of the FZD7-expressing cells might result in depletion of the stem/progenitor cell fraction assayed by sphere-formation and clonogenic ability ((Singh et al., 2004), (Fillmore & Kuperwasser, 2008; Somervaille & Cleary, 2006).
  • FZD7-sensitive WT were treated with anti-FZD7 for several time periods and the sphere-forming ability of the remaining WT cells at each time point was evaluated.
  • Anti-FZD7Ab reduces proliferation/ survival oj ' FZD? '-sensitive WT cells grafted to the chick embryo
  • CAM chorioallantoic membrane
  • the present inventors investigated potential mechanisms regulating their expression.
  • Both sFRPl and DKKl are known to be epigenetically modified in various types of cancer (Jost et al., 2008; Nojima et al, 2007; Suzuki et al, 2008). Nevertheless, epigenetic regulation of sFRPl and DKKl has yet to be demonstrated in WT.
  • the present inventors therefore treated both FZD7-sensitive and resistant WT cells with the de-methylating agents AzaC and TSA and studied their effects on expression of the Wnt inhibitors.
  • FZDl receptor trafficking and localization hampers cell sorting in FZD7 -resistant
  • FZD7 is not a reliable surface marker for repeated cell sorting required to assess tumor-initiating capacity in vivo.
  • FZD7 Over all the present inventors were able to analyze sorted FZD7(+) and FZD7(-) cells from three separations in which such conditions were apparent ( Figures lOC-D). In these cases, FZD7(+) cells were found to be both highly clonogenic, and proliferative compared to the negative fraction ( Figures 10E-H). In addition, the FZD7(+) cell fraction was shown to overexpress WT 'sternness' genes, nephric-progenitor (Six2, SaM), polycomb (Bmi-1), pluripotency and self renewal (Oct4).
  • NCAM + FZD7 + NCAM is a putative marker for the malignant renal progenitor population [Pode-Shaled et al, 2008] and immunostaining for NCAM and FZD7 in WT revealed both to mark blastemal cells in addition to other structures ( Figures 1 IA-D). Due to inherent limitations (see above) this attempt yielded one successful sorting of NCAM + FZD7 + cells ( Figures 1 IE-G), which when followed by CFU formation assay, showed higher colony formation ability and a significantly elevated cell number in each colony ( Figures 1 IH-I). Since a negative NCAM FZD7 " cell fraction could not be obtained; NCAM + FZD7 + cells were compared to the NCAM " fraction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une méthode permettant de détruire une cellule cancéreuse qui exprime des NCAM et éventuellement des FZD7. Ladite méthode comprend la mise en contact de la cellule cancéreuse avec une partie cytotoxique et une partie ciblant les NCAM, ce qui permet la destruction de la cellule cancéreuse.
PCT/IL2010/000554 2009-07-10 2010-07-08 Compositions et méthodes de traitement du cancer WO2011004379A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21375709P 2009-07-10 2009-07-10
US61/213,757 2009-07-10

Publications (1)

Publication Number Publication Date
WO2011004379A1 true WO2011004379A1 (fr) 2011-01-13

Family

ID=42676819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2010/000554 WO2011004379A1 (fr) 2009-07-10 2010-07-08 Compositions et méthodes de traitement du cancer

Country Status (1)

Country Link
WO (1) WO2011004379A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130364A1 (fr) * 2012-02-28 2013-09-06 Novartis Ag Sélection de patient atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43
WO2015101998A1 (fr) * 2014-01-02 2015-07-09 The Chaim Sheba Medical Center Anticorps de liaison au récepteur frizzled pour le traitement du cancer
US9260519B2 (en) 2011-06-17 2016-02-16 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
US9296826B2 (en) 2011-10-14 2016-03-29 Novartis Ag Antibodies and methods for WNT pathway-related diseases

Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3791932A (en) 1971-02-10 1974-02-12 Akzona Inc Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3839153A (en) 1970-12-28 1974-10-01 Akzona Inc Process for the detection and determination of specific binding proteins and their corresponding bindable substances
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US3879262A (en) 1972-05-11 1975-04-22 Akzona Inc Detection and determination of haptens
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5204096A (en) 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6326174B1 (en) 1994-12-02 2001-12-04 The Scripps Research Institute Enzymatic DNA molecules
US6348185B1 (en) 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20030082188A1 (en) * 2001-10-11 2003-05-01 Tso J. Yun Treatment of prostate cancer by inhibitors of NCAM2
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006055635A2 (fr) * 2004-11-15 2006-05-26 Mount Sinai School Of Medicine Of New York University Compositions et methodes de modification de la signalisation autocrine wnt
WO2007053577A2 (fr) * 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions et procedes pour diagnostiquer et traiter un cancer
EP1832605A1 (fr) * 2006-03-07 2007-09-12 Universität Zu Köln Anticorps se liant à la neural cell adhesion molecule (NCAM)
US20090111177A1 (en) 2003-12-19 2009-04-30 The Rockefeller University Maintenance of Embryonic Stem Cells by the GSK-3 Inhibitor 6-Bromoindirubin-3'-Oxime
US7537931B2 (en) 1999-06-25 2009-05-26 Genentech, Inc. Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies
WO2010037041A2 (fr) * 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
WO2010062143A2 (fr) * 2008-11-27 2010-06-03 한국생명공학연구원 Composition anticancéreuse comprenant une substance et un agent antitumoraux et présentant des effets inhibiteurs sur l'activité et l'expression de l1cam

Patent Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US3839153A (en) 1970-12-28 1974-10-01 Akzona Inc Process for the detection and determination of specific binding proteins and their corresponding bindable substances
US3791932A (en) 1971-02-10 1974-02-12 Akzona Inc Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US3879262A (en) 1972-05-11 1975-04-22 Akzona Inc Detection and determination of haptens
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5204096A (en) 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202B1 (fr) 1985-03-28 1990-11-27 Cetus Corp
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6326174B1 (en) 1994-12-02 2001-12-04 The Scripps Research Institute Enzymatic DNA molecules
US6348185B1 (en) 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7537931B2 (en) 1999-06-25 2009-05-26 Genentech, Inc. Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies
US20030082188A1 (en) * 2001-10-11 2003-05-01 Tso J. Yun Treatment of prostate cancer by inhibitors of NCAM2
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20090111177A1 (en) 2003-12-19 2009-04-30 The Rockefeller University Maintenance of Embryonic Stem Cells by the GSK-3 Inhibitor 6-Bromoindirubin-3'-Oxime
WO2006055635A2 (fr) * 2004-11-15 2006-05-26 Mount Sinai School Of Medicine Of New York University Compositions et methodes de modification de la signalisation autocrine wnt
WO2007053577A2 (fr) * 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions et procedes pour diagnostiquer et traiter un cancer
EP1832605A1 (fr) * 2006-03-07 2007-09-12 Universität Zu Köln Anticorps se liant à la neural cell adhesion molecule (NCAM)
WO2010037041A2 (fr) * 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
WO2010062143A2 (fr) * 2008-11-27 2010-06-03 한국생명공학연구원 Composition anticancéreuse comprenant une substance et un agent antitumoraux et présentant des effets inhibiteurs sur l'activité et l'expression de l1cam

Non-Patent Citations (71)

* Cited by examiner, † Cited by third party
Title
A. HASSNER ET AL., TETRAHEDRON LETT., 1978, pages 4475
AOKI ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 231, 1997, pages 540 - 5
B. NEISES ET AL., ANGEW CHEM., INT. ED. ENGL., vol. 17, 1978, pages 522
BHARGAVA A ET AL., BRAIN RES. PROTOC., vol. 13, 2004, pages 115 - 125
BILLY ET AL., PNAS, vol. 98, 2001, pages 14428 - 14433
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BOERNER ET AL., J. IMMUNOL., vol. 147, no. 1, 1991, pages 86 - 95
BREAKER, R.R.; JOYCE, G., CHEMISTRY AND BIOLOGY, vol. 2, 1995, pages 655
CUMBER ET AL., METHODS OF ENZYMOLOGY, vol. 112, 1985, pages 207 - 224
DATABASE WPI Week 201041, Derwent World Patents Index; AN 2010-G09597, XP002600597 *
DIALLO ET AL., OLIGONUCLEOTIDES, vol. 13, no. 5, 1 October 2003 (2003-10-01), pages 381 - 392
DIALLO M. ET AL., OLIGONUCLEOTIDES, vol. 13, 2003, pages 381 - 392
E.P. BODEN ET AL., J. ORG. CHEM., vol. 50, 1986, pages 2394
FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 51
GERWITZ, CURR OPIN MOL THER, vol. 1, 1999, pages 297 - 306
GRISHOK ET AL., CELL, vol. 106, 2001, pages 23 - 34
GUO ET AL., PLANT CELL, vol. 17, 2005, pages 1376 - 1386
HAMMOND ET AL., SCIENCE, vol. 293, 2001, pages 1146 - 1150
HOLMUND ET AL., CURR OPIN MOL THER, vol. 1, 1999, pages 372 - 85
HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1991, pages 381
HUTVAGNER ET AL., SCIENCE, vol. 293, 2001, pages 834 - 838
HUTVAGNER ET AL., SCIENCEXPRESS, vol. 297, 2002, pages 2056 - 2060
INBAR ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 69, pages 2659 - 62
ITOH ET AL., ANN MEETING AM SOC GEN THER, 2002
JENSEN ET AL: "Targeting the neural cell adhesion molecule in cancer", CANCER LETTERS, NEW YORK, NY, US LNKD- DOI:10.1016/J.CANLET.2007.09.004, vol. 258, no. 1, 18 October 2007 (2007-10-18), pages 9 - 21, XP022310543, ISSN: 0304-3835 *
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KETTING ET AL., GENES DEV., vol. 15, 2001, pages 2654 - 2659
KHACHIGIAN, LM, CURR OPIN MOL THER, vol. 4, 2002, pages 119 - 21
KRONENWETT ET AL., BLOOD, vol. 91, 1998, pages 852 - 62
L.J. MATHIAS, SYNTHESIS, 1979, pages 561
LARRICK; FRY, METHODS, vol. 2, 1991, pages 106 - 10
LAVIGNE ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 237, 1997, pages 566 - 71
LEE ET AL., CELL, vol. 75, 1993, pages 843 - 854
LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859
LONBERG; HUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93
LUFT, J MOL MED, vol. 76, 1998, pages 75 - 6
MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581
MATVEEVA ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 1374 - 1375
MORRISON, NATURE, vol. 368, 1994, pages 812 - 13
MOURLATOS ET AL., GENES DEV., vol. 16, 2002, pages 720 - 728
NEUBERGER, NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 826
NUCLEIC ACIDS RESEARCH, vol. 34, no. 13, 2006, pages 3803 - 3810
O'NEIL M ET AL: "The Merck Index", vol. 14, 2006, MERCK & CO., INC., Whitehouse Station, NJ, USA, XP002612807 *
O'NEIL M ET AL: "The Merck Index", vol. 14, 2006, MERCK & CO., INC., Whitehouse Station, NJ, USA, XP002612808 *
PACK ET AL., BIO/TECHNOLOGY, vol. 11, 1993, pages 1271 - 77
PADDISON P.J. ET AL., PROC. NATL ACAD. SCI. USA., vol. 99, 2002, pages 1443 - 1448
PARIZOTTO ET AL., GENES & DEVELOPMENT, vol. 18, 2004, pages 2237 - 2242
PODE-SHAKKED NAOMI ET AL: "Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, UNIVERSITY PRESS CAROL DAVILA, BUCHAREST, RO, vol. 13, no. 8B, 16 December 2008 (2008-12-16), pages 1792 - 1808, XP002581529, ISSN: 1582-1838, [retrieved on 20081216], DOI: DOI:10.1111/J.1582-4934.2008.00607.X *
PORTER, R. R., BIOCHEM. J., vol. 73, 1959, pages 119 - 126
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
RAJUR ET AL., BIOCONJUG CHEM, vol. 8, 1997, pages 935 - 40
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
SANTORO, S.W.; JOYCE, G.F., PROC. NATL, ACAD. SCI. USA
SANTORO, S.W.; JOYCE, G.F., PROC. NATL, ACAD. SCI. USA, vol. 943, 1997, pages 4262
SHINAGWA; ISHII, GENES & DEV., vol. 17, no. 11, 2003, pages 1340 - 1345
TANAKA J -I ET AL: "Preparation of a conjugate of mitomycin C and anti-neural cell adhesion molecule monoclonal antibody for specific chemotherapy against biliary tract carcinoma", SURGERY TODAY 1998 JP LNKD- DOI:10.1007/S005950050319, vol. 28, no. 11, 1998, pages 1217 - 1220, XP002600590, ISSN: 0941-1291 *
TRAN N. ET AL., FEBS LETT., vol. 573, 2004, pages 127 - 134
TUSCHL, CHEMBIOCHEM., vol. 2, pages 239 - 245
UENO K ET AL: "Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells", BRITISH JOURNAL OF CANCER 20091020 NATURE PUBLISHING GROUP GBR LNKD- DOI:10.1038/SJ.BJC.6605307, vol. 101, no. 8, 20 October 2009 (2009-10-20), pages 1374 - 1381, XP002612806, ISSN: 0007-0920 *
UENO K ET AL: "Frizzled-7 as a potential therapeutic target in colorectal cancer", NEOPLASIA 200807 US LNKD- DOI:10.1593/NEO.08320, vol. 10, no. 7, July 2008 (2008-07-01), pages 697 - 705, XP002612805, ISSN: 1522-8002 *
UNO ET AL., CANCER RES, vol. 61, 2001, pages 7855 - 60
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
WALTON ET AL., BIOTECHNOL BIOENG, vol. 65, 1999, pages 1 - 9
WELCH ET AL., CLIN DIAGN VIROL., vol. 10, 1998, pages 163 - 71
WELCH ET AL., CURR OPIN BIOTECHNOL., vol. 9, 1998, pages 486 - 96
WHITLOW; FILPULA, METHODS, vol. 2, 1991, pages 97 - 105
WIGHTMAN ET AL., CELL, vol. 75, 1993, pages 855 - 862
WILLIAMS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 6889 - 6894
ZENG ET AL., MOLEC. CELL, vol. 9, 2002, pages 1327 - 1333

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260519B2 (en) 2011-06-17 2016-02-16 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
US9765401B2 (en) 2011-06-17 2017-09-19 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
US9296826B2 (en) 2011-10-14 2016-03-29 Novartis Ag Antibodies and methods for WNT pathway-related diseases
WO2013130364A1 (fr) * 2012-02-28 2013-09-06 Novartis Ag Sélection de patient atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43
CN104302782A (zh) * 2012-02-28 2015-01-21 诺华股份有限公司 利用rnf43突变状态选择wnt信号转导抑制剂给药的癌症患者
EP3693476A1 (fr) * 2012-02-28 2020-08-12 Novartis AG Sélection de patients atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43
WO2015101998A1 (fr) * 2014-01-02 2015-07-09 The Chaim Sheba Medical Center Anticorps de liaison au récepteur frizzled pour le traitement du cancer
JP2017506214A (ja) * 2014-01-02 2017-03-02 テル ハシュオマー−メディカル リサーチ インフラストラクチャー アンド サービシーズ リミテッド 癌を治療するためのＦｒｉｚｚｌｅｄ受容体抗体
US10465004B2 (en) 2014-01-02 2019-11-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Frizzled receptor antibodies for treatment of cancer

Similar Documents

Publication Publication Date Title
KR101875227B1 (ko) 항-ｃｅａｃａｍ1 항체들과 이를 이용하는 방법들
JP5525689B2 (ja) 過剰増殖性障害を処置するための組成物および方法
EP2573120A1 (fr) Anticorps anti-trop-2 humain ayant une activité anticancéreuse in vivo
WO2018044937A2 (fr) Compositions et méthodes de traitement d'un cancer déficient en suppresseurs tumoraux
JP2016502536A (ja) 腫瘍転移を防止し、がんを処置および予後診断し、推定転移阻害剤である薬剤を同定する方法
JP7569741B2 (ja) 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法
EP3507360A1 (fr) Compositions et méthodes de traitement d'un cancer déficient en suppresseur de tumeur
US10105384B2 (en) Nucleic acids targeting TCTP for use in the treatment of chemo- or hormone-resistant cancers
US20190271702A1 (en) Methods of treatement of cancer disease by targetting tumor associated macrophage
WO2011004379A1 (fr) Compositions et méthodes de traitement du cancer
Sana et al. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines
EP2699599B1 (fr) Gpr177 en tant que cible et marqueur dans des tumeurs
JP2022530339A (ja) インテグリンα１０および侵攻性癌型
CN103800919B (zh) Tuft1在制备肝癌诊断和治疗制剂中的应用
US12134650B2 (en) Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer
WO2021024263A1 (fr) Compositions ciblant la gpm6a et méthodes pour le diagnostic et le traitement du cancer
WO2016092301A1 (fr) Ciblage vasculaire
Wang et al. ARTICLE H
WO2025068180A1 (fr) Méthodes de traitement du cancer par ciblage des fibroblastes associés au cancer
CN118510542A (zh) 用于处置癌的药物组合物
KR101753457B1 (ko) 암 줄기 유사세포 검출용 바이오마커 ｇｐｒ５０ 및 이의 용도
WO2025068157A1 (fr) COMBINAISON D'UN ANTAGONISTE DE βIG-H3 ET D'UN ANTAGONISTE DE PDFG-AA POUR LE TRAITEMENT DU CANCER

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10742911

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10742911

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载